Form 4: Forte Biosciences Director Barbara K. Finck Acquires 31,000 Stock Options
SEC Form 4 Filing
Director Barbara K. Finck acquired 31,000 stock options in Forte Biosciences, Inc. on March 19, 2025.
Summary
- On March 19, 2025, Barbara K. Finck, a director of Forte Biosciences, Inc., acquired 31,000 stock options.
- The exercise price of these options is $7.02.
- The options vest monthly over three years, starting from January 1, 2025, contingent upon continued service as a Service Provider.
- The options expire on March 19, 2035.
- Following the transaction, Finck directly owns 31,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition. While insider ownership can be a positive signal, this is just a standard grant.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting schedule of the options is contingent upon the reporting person continuing to be a service provider, suggesting an expectation of continued involvement with the company.
Industry Context
This is a standard disclosure related to insider transactions, common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.
Comparison to Industry Standards
- Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.
- The vesting schedule of one-thirty-sixth per month is a typical vesting arrangement.
- Similar grants can be seen at companies like Amgen, Biogen, and Regeneron, where stock options are used to incentivize key personnel.
Stakeholder Impact
- The acquisition of stock options by a director can align their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| January 1, 2025 | Vesting Commencement Date for the stock options. |
| March 19, 2025 | Date of the transaction where Barbara K. Finck acquired stock options. |
| March 21, 2025 | Date of signature for the Form 4 filing. |
| March 19, 2035 | Expiration date of the stock options. |
Keywords
Forte Biosciences, Director, Stock Options, Acquisition, Beneficial Ownership, Form 4, FBRX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.